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Ras of complex proteins (ROC) domains were identified in 2003 as GTP bindingmodules in largemultidomain
proteins from Dictyostelium discoideum. Research into the function of these domains exploded with their
identification in a number of proteins linked to human disease, including leucine-rich repeat kinase 2
(LRRK2) and death-associated protein kinase 1 (DAPK1) in Parkinson’s disease and cancer, respectively.
This surge in research has resulted in a growing body of data revealing the role that ROC domains play in
regulating protein function and signaling pathways. In this review, recent advances in the structural informa-
tion available for proteins containing ROC domains, along with insights into enzymatic function and the
integration of ROC domains as molecular switches in a cellular and organismal context, are explored.The Ras of complex proteins (ROC) domain was first established
as a distinct protein domain family following the identification of a
guanosine triphosphate (GTP) binding motif in a series of large
multidomain proteins in the Amoeba Dictyostelium discoideum
(Bosgraaf and Van Haastert, 2003). Since 2003, ROCO proteins
have been identified in a range of species, from prokaryotes to
humans. Interest in the structure and function of ROC domains
increased with the identification of links between several pro-
teins containing ROC domains and human disease: most
notably, leucine-rich repeat kinase 2 (LRRK2) with Parkinson’s
disease (PD) and death-associated protein kinase 1 (DAPK1)
with cancer. ROC domains likely act asmolecular switches, con-
trolling function and, through this, the cellular role of the proteins
within which they reside. This has led to analogies being drawn
between ROC domains and the function of small GTPases
such as Ras, as well as G protein a subunits. Over the past
five years, our understanding of these proteins has been much
improved by structural studies, in vitro and cellular analysis of
function, and in vivo modeling. What emerges from these data
is an incomplete but tantalizing picture of ROC domain function,
the highly complicated mechanisms by which these domains are
regulated, and the pathways that they control.
Evolutionary and Genetic Perspective
Proteins containing ROC domains have been recognized and
studied for almost two decades (Deiss et al., 1995); however,
the first formal description of the ROCO protein family dates
from 2003 (Bosgraaf and Van Haastert, 2003). This family com-
prises proteins with ROC, invariably followed by a domain
termed COR (C-terminal of ROC). Phylogenetic analysis of
different ROC domains revealed a monophyletic group distinct
from the rest of the GTPases (Bosgraaf and Van Haastert,
2003). There are no clear examples of ROC or COR domainsoccurring in isolation, suggesting that the ROC-COR is
likely to be a single functional unit. Another unique property of
ROC-COR is that it always sits in multidomain proteins, from
the simplest arrangement observed for animal MFHAS1 or plant
Tornado proteins where ROC-COR is N-terminally preceded by
leucine-rich repeats (LRRs) to the complex multidomain GbpC
protein of D. discoideum that contains nine domains (Marı´n
et al., 2008).
Although ROC domains have garnered considerable interest,
their biological function is still poorly understood. From an
evolutionary perspective, ROC domains are present among
the most ancient and simple living organisms, including
bacteria. Prokaryotic ROC domains are part of multidomain pro-
teins that typically possess N-terminal LRRs and a C-terminal
ROC-COR unit. The best-characterized bacterial ROC domain
is found in the thermophilic green sulfur bacteria Chlorobium
tepidum. A similar architecture is also present in other gram
positive bacteria such as purple bacteria and cyano-
bacteria. Archaea also possess ROC domains with a similar
architecture (Doolittle, 2000). However, blastp searches using
C. tepidum (bacteria) or M. Barkeri (archaea) COR domains
against myxobacteria sequences reveal no significant domain
conservation. Although it is unclear whether ROC domains orig-
inated in prokaryotes or were instead horizontally transferred
from eukaryotes, their presence in both archaea and bacteria
suggest an ancient origin (Marı´n et al., 2008). The Amoebozoan
slim mold D. discoideum possesses 11 ROCO genes, which are
thought to have evolved recently from prokaryotic ROCO genes
(Marı´n et al., 2008). D. discoideum ROCO genes have been
extensively studied, revealing their involvement in chemotaxis
and also in cell division and development through control of
cytoskeleton dynamics (van Egmond and van Haastert, 2010).
The D. discoideum ROCO gene GbpC regulates cytoskeletonChemistry & Biology 21, July 17, 2014 ª2014 The Authors 809
Figure 1. Putative Proteins Containing ROC-COR Domains from T. adherens
Proteins were identified using blastp searches with D. discoideum COR domains against T. adherens genome (TAXID: 10228). TRP, tetratricopeptide domain;
AAA, ATPase domain; MBT, malignant brain tumor repeats; SH3, SRC homology 3 domain; LRRs, leucine-rich repeats; CARD, caspase recruitment domain; TIR,
Toll-interleukin receptor domain.
Chemistry & Biology
Reviewassembly by cGMP-dependent phosphorylation of myosin II
upon cAMP stimulation (Kortholt et al., 2012; van Egmond
et al., 2008). Lack of ROCO genes in fungi and yeasts, where
chemotaxis (movement of cells in response to external chemical
stimuli) is less important for their life cycle compared to slime
molds (Arkowitz, 1999), suggests that these genes play a role
in cytoskeleton-related processes culminating in cellular or sub-
cellular movements.
A recent bioinformatics analysis of myotubularin genes in
eukaryotes identified a novel group containing ROC domains in
another Amoebozoan, Entamoeba histolytica (Kerk and Moor-
head, 2010). Myotubularins belong to the tyrosine phosphatase
family and act as lipid phosphatases cleaving the D3 phosphate
from phosphatidylinositol phospholipids (Schaletzky et al.,
2003). These phospholipids localize to intracellular membranes
and to plasma membrane microdomains and rafts, and they
are thought to mediate vesicular trafficking, the transition
between endosomes and lysosomes, retromer transport, and
endocytosis in a phosphorylation-dependent manner (Clague
and Lorenzo, 2005). Kerk and Moorhead found a large set of
19 myotubularin genes in E. histolytica, 9 of which contain
inactive myotubularin at the N terminus followed by LRRs,
ROC-COR, and kinase domains. They called this novel architec-
ture IMLRK (inactive myotubularin-LRRs-ROCO-kinase) (Kerk
andMoorhead, 2010). Compared toD. discoideum, the life cycle
of E. histolytica is simpler; however, complex membrane remod-
eling processes linked to invasive contact with host tissue likely
require a large collection of myotubularins to be finely regulated
in time and space. Interestingly, extensive data support a role for
human LRRK2 in vesicular trafficking (Beilina et al., 2014; Piccoli
et al., 2011; Shin et al., 2008) lipid raft association (Hatano et al.,
2007), and exosome formation (Fraser et al., 2013), supporting a
role for ROC domains in lipid remodeling.810 Chemistry & Biology 21, July 17, 2014 ª2014 The AuthorsA bioinformatic analysis of ROC domains in Trichoplax
adhaerens, the only species of the phylum placozoa and the
most ancient metazoan known, reveals the presence of multiple
ROCO genes. T. adherens is a simple, disc-shaped organism
with two epithelial layers covering an inner layer of fiber
cells and no apparent nerve, muscle, or sensory cells (Srivastava
et al., 2008). Using multiple blastp searches, at least 17
putative ROCO genes can be identified in T. adherens
(Figure 1). As shown in Figure 1, all putative protein
products contain an ROC-COR domain surrounded by other
functional domains, including CARD and death domains,
tetratricopeptide (TRP) and LRRs repeats, and ATPase domains
of the AAA family. Of interest, at least three putative protein
products are predicted to contain Ras-like domains N-terminally
of ROC (TRIADDRAFT_62404, TRIADDRAFT_62498, and
TRIADDRAFT_57945). This arrangement is novel and particularly
intriguing as two GTP binding and/or GTPase domains are
present in the same protein, and it may support a model where
the ROC-COR unit functions as a nucleotide-dependent dimer-
ization device while the Ras-like GTPase acts as the signaling
output (analogous to kinase domains found in some ROCO pro-
teins). Whether this model is correct and can be extended to
other ROCO proteins remains to be investigated. Another point
to consider is why two divergent species such as slime molds
and placozoa have independently undergone multiple gene
duplication events to expand their set of proteins with ROC
domains. Functionally, both organismsmove in response to che-
moattractants and feed by phagocytosis (Srivastava et al., 2008;
van Egmond and van Haastert, 2010). Based on the established
role ofD. discoideumGbpC protein in chemotaxis and the role of
human ROCO proteins in processes related to phagocytosis in
response to host infection (MASL1 and LRRK2), it can be
speculated that slime molds and placozoa have independently
Figure 2. Phylogenetic Relationships among ROCO Proteins
(A) Phylogenetic dendograms (constructed using the unweighted pair-group method of analysis) based on the full-length amino acid sequences of prokaryotes
(C. tepidum), archea (M. barkeri), placozoa (T. adherens), slime mold (D. discoideum), plants (A. thaliana), invertebrates (C. elegans and D. melanogaster), and
vertebrates (D. rerio and H. sapiens). Of note, the closest homolog of human DAPK1 is plant Tornado1; MFHAS1 proteins are closer to Dyctiostelium ROCO than
to LRRKs; and Drosophila LRRK and Caenorabditis LRK-1 are closer to LRRK1 than to LRRK2.
(B) Phylogenetic dendograms from the same species using the predicted ROC-COR domains. LRRK1’s closest ROC-COR domain is LRRK2.
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evolution.
There are other examples of organisms possessing multiple
ROCO genes. Zambounis et al. identified 37 LRR-GTPases of
the ROCO family in the brown algae Ectocarpus siliculosus by
using bioinformatic searches (Zambounis et al., 2012). The
majority of Ectocarpus ROCO proteins have N-terminal LRRs
followed by an ROC-COR domain and a C-terminal domain ho-
mologous either to other ROCO proteins or to transmembrane
proteins. The authors found that the majority of ROCO loci are
organized in clusters and that the LRR of all ROCO proteins
(with one exception) exhibit a repetitive intro-exon structure
where each LRR is encoded by a 72-nucletide/24-amino-acid-
long individual exon also present in noncoding regions. This
striking arrangement suggesting highly dynamic exon shuffling,
together with the remarkable expansion of the Ectocarpus
ROCO family, hints that Ectocarpus ROCO proteins may be
involved in immune response mechanisms. A role of ROC
domains in immune response mechanisms is gaining attention
among human ROCO proteins; for example, MASL1 and
LRRK2 have been shown to be upregulated upon pathogen
infection (Gardet et al., 2010; Ng et al., 2011). Although the
molecular mechanisms through which human ROCO proteins
modulate inflammatory response are still unclear, the LRRs of
LRRK2 display a significant similarity to those found in NOD-2
(Hakimi et al., 2011), an intracellular recognition receptor,
suggesting that LRRK2, and possibly MASL1, may function as
cytoplasmic receptors initiating NF-kB signaling in response to
various danger signals and pathogen-associated molecular
patterns.As discussed, cyanobacteria possess ROC domains, but this
is not true for all photosynthetic organisms. Bioinformatic
searches for conserved ROC-COR domains in green algae,
ferns, gymnosperms, and angiosperms reveal that only flowering
plants possess ROCO genes, named Tornado1 proteins. These
proteins possess N-terminal LRRs, a ribonuclease-inhibitor-like
subfamily, and a C-terminal ROC-COR. Knockout (KO) studies
of Arabidopsis thaliana TORNADO1 gene revealed that Tor-
nado1, together with Tornado2 (a tetraspanin protein), is
involved in leaf patterning processes including leaf symmetry
and venation patterning (Cnops et al., 2006). Due to the limited
number of studies on Tornado1 proteins in plants, their function
is poorly understood, as is the role of ROC domains in the
signaling processes mediated by these proteins.
The evolutionary history of ROCO genes in animals has been
thoroughly reconstructed by Marin (Marı´n et al., 2008). Proto-
stomes and deuterostomes possess LRRK and DAPK1 genes,
while only deuterostomes have MFHAS1 genes. The phyloge-
netic relationships among prokaryotes, archea, placozoa, slime
molds, plants, invertebrates, and vertebrates ROCO proteins
are shown in Figure 2.
Several groups have reported evidence for multiple splice
variants of the LRRK2 gene. A study by Giesert et al. examined
splicing of LRRK2 in the mouse brain, uncovering evidence of
altered splicing of exon 5 and a novel exon 42 (located within
the kinase domain of this protein) (Giesert et al., 2013). Of direct
relevance to ROC domain function, Trabzuni and colleagues
reported that LRRK2 may undergo alternative splicing events
around exons 32 and 33 in the substantia nigra (Trabzuni et al.,
2013). Although these observations are limited to the RNA levelChemistry & Biology 21, July 17, 2014 ª2014 The Authors 811
Figure 3. Functional Interactions between the ROC Domain and
Other Protein Domains Associated with It
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corresponding protein isoforms, it is noteworthy that this nucle-
otide region corresponds to the ROC-COR domain of LRRK2. It
could be speculated that these substantia-nigra-specific LRRK2
isoforms lacking part of the ROC-COR may play a pathological
function by acting, for instance, as dominant negative. It is likely
that these reports represent the tip of the iceberg with regard to
splicing of ROC domain containing genes, and much more
remains to be uncovered regarding all of the ROCO proteins.
Functional Conservation of ROC Domain Activity
With regard to the biological function of the ROC domain,
guanosine nucleotide binding and hydrolysis have been demon-
strated for several ROCO proteins. Guanosine nucleotide
binding has been reported for the four human ROCO proteins
(Carlessi et al., 2011; Dihanich et al., 2014; Ito et al., 2007; Jebelli
et al., 2012; Korr et al., 2006). Whether the ability to bind GTP is
conserved in other organisms has been tested in two cases—for
the D. discoideum ROCO protein GbpC (van Egmond et al.,
2008) and for the C. tepidum ROCO protein (Gotthardt et al.,
2008). Based upon sequence homology and extant functional
data, it is likely that ROC domains where key catalytic residues
are conserved are able to bind nucleotides.
The ability of ROC domains to hydrolyze GTP has been
investigated for a number of ROCO proteins. Several groups
have demonstrated that LRRK2 is able to bind and hydrolyze
GTP (Guo et al., 2007; Lewis et al., 2007; Li et al., 2007).
DAPK1 has also been reported to possess GTPase activity
(Carlessi et al., 2011).
An important aspect of ROC domain biology is the impact of
guanosine nucleotide binding on the structure and function of
neighboring domains. The majority of ROCO proteins have func-
tional domains (including enzymatic activities) in addition to their
ROC domains. An early observation was that manipulating the
GTP binding properties of LRRK1 had a major impact on the
kinase activity of this protein, leading the authors to propose a
model for LRRK1 function, and by implication the ROCOproteins
(Korr et al., 2006). In this model, the cycle between GTP-bound
and GDP-bound ROC controls the kinase activity of LRRK1 in
a manner analogous to the control of Raf kinase activity by the
Ras proteins. These data were supported by studies investi-
gating LRRK2, with artificial mutations excluding guanosine
nucleotides reducing kinase activity (Ito et al., 2007). More recent812 Chemistry & Biology 21, July 17, 2014 ª2014 The Authorsdata suggest that the kinase activity of this protein is dependent
upon whether a guanosine nucleotide of any type is bound to the
ROC domain (Taymans et al., 2011). This is consistent with a
model proposed by Gasper and coworkers, suggesting that
ROC domains act in a similar fashion to G proteins, dimerizing
upon GTP binding (Gasper et al., 2009). An insight into the rela-
tionship between ROC domains and the other functions of the
ROCO proteins is provided by two recent reports investigating
ROC domain function in DAPK1 (Carlessi et al., 2011; Jebelli
et al., 2012). The kinase domain of DAPK1 sits at the extreme
N terminus of the protein, in contrast to LRRK1 and LRRK2
where the kinase domain sits in the C terminus of the protein.
When guanosine nucleotide binding is disrupted by artificial
mutations in DAPK1, kinase activity does not decrease. This
clear divergence from the biology of LRRK2 suggests that the
role of ROC domains in controlling other enzymatic functions is
complicated and is likely to be dictated by the 3D organization
of these domains.
A final aspect of the relationship between the ROCdomain and
its flanking enzymatic activities or regulatory domains is the
reciprocity of these relationships. Data from LRRK2 have high-
lighted the presence of a number of autophosphorylation sites
within the ROC domain of this protein. While the physiological
role of these phosphorylation events remains unclear, their iden-
tification suggests that a complex pattern of regulation exists
between the different enzymatic activities of the ROCO proteins.
Phosphorylation of the ROC domain may act to regulate guano-
sine nucleotide binding (Webber et al., 2011). One caveat is that
mutation of individual autophosphorylation sites may have a
structural rather than functional impact, as suggested by the
fact that kinase-inactive mutants are competent in binding and
hydrolyzing GTP (Biosa et al., 2013). The possible interactions
between the ROC-COR domain and surrounding domains are
summarized in Figure 3. This area of ROC biology bears greater
scrutiny: for example, the D. discoideum ROCO protein Gbpc,
which possesses a C-terminal guanine exchange factor (GEF)
domain in addition to its ROC and kinase activities. Examination
of Gbpc biology suggests that this GEF domain interacts with
and regulates the ROC activity of this protein, adding further
complexity (van Egmond et al., 2008).
Structural Perspective
The production of highly pure, full-length recombinant ROCO
proteins for structural studies is challenging. To date, no full-
length ROCO protein structures have been solved, with limited
data available for the ROC-COR or ROC alone (Deng et al.,
2008; Gotthardt et al., 2008; Liao et al., 2014). Published in
2008, the first structure of the ROC domain from the human
ROCO protein LRRK2 revealed a dimeric GTPase (Deng et al.,
2008). Although the proposed model describes a canonical
GTPase fold, the catalytic core of LRRK2-ROC adopts an
unusual topology because of domain swapping, in which the
N-terminal part of one domain interacts with the C-terminal
one of the other. In the same year, a crystallographic study of
the ROC-COR unit from the bacteria C. tepidum was published
confirming the dimeric organization of the ROCO proteins. In
contrast to the previously determined structure of the human
ROC domain, the structural analysis revealed a canonical G pro-
tein domain where dimerization is mediated by the C-terminal
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ROC-ROC interface (Gotthardt et al., 2008). More recently, Liao
and coworkers derived a monomeric model structure for the hu-
man ROC domain (Liao et al., 2014). While the nucleotide free
formof this protein formed amixture of themonomer and dimeric
complex, GDP or GppNHp binding caused the ROC domain to
adopt a monomeric conformation, potentially consistent with
data investigating the kinase activity of LRRK2 and the G protein
activated by the nucleotide-dependent dimerization (GAD)
model for ROCO function. Studies of isolated ROC domains
are obviously limited with regard to the quaternary structure of
ROCO proteins. As described for dynamins, other domains
may be required for dimerization and/or oligomerization.
Although high-resolution data for ROCO protein tertiary struc-
tures are limited, it is probably that LRRK2 and other members of
the ROCO family are functional dimers (Berger et al., 2010; Greg-
gio et al., 2008; Jebelli et al., 2012; Klein et al., 2009; Sen et al.,
2009). The hypothesis of a homodimeric or heterodimeric
conformation by the ROCO family is also supported by a growing
body of literature based on size exclusion chromatography
assays and immunogold labeling transmission electron micro-
scopy analysis of full-length purified proteins (Carlessi et al.,
2011; Civiero et al., 2012; Dihanich et al., 2014; Greggio et al.,
2008; Jebelli et al., 2012).
Due to their low affinity (in the range of mM) for nucleotides (Civ-
iero et al., 2012; Gotthardt et al., 2008) and to their capability to
dimerize or oligomerize (Civiero et al., 2012; Sen et al., 2009),
the ROCO proteins were recently suggested to act as GADs, a
category including dynamin and septins (Gasper et al., 2009).
GADs are a group of proteins that do not require GEFs to
exchange GDP for GTP (Gasper et al., 2009). The GTP-bound
dimer is the active form that is responsible for the biological pro-
cess, which is terminated by hydrolysis of GTP. Supporting the
hypothesis of ROCO proteins as functional dimers, it was shown
that the ROC-COR module from C. tepidum depends on a
dimeric conformation to hydrolize GTP, with mutations analo-
gous to the ROC-COR Parkinson disease mutations (R1441C,
Y1699C, I1371V) located in the ROC-COR interface leading to a
reduction of GTPase activity (Gotthardt et al., 2008). In addition,
human LRRK2 purified proteins carrying R1441C or Y1699C
mutations that show a disrupted GTPase activity (Danie¨ls et al.,
2011; Lewis et al., 2007) bind the ROC domain with less affinity
in vitro compared to the wild-type protein (Li et al., 2009a).
Cellular and Organismal Function
The ROCO proteins have been implicated in a range of cellular
processes. In slime molds, the key phenotype with which they
are linked is chemotaxis (Bosgraaf et al., 2002). KO of GbpC
and Pats1 modulate chemotaxis and cytokinesis, respectively
(Bosgraaf et al., 2005; Abysalh et al., 2003). Studies of both
GbpC and Pats1 highlight one of the major confounding issues
in studying ROC domain biology: separating out whether a given
phenotype is associated with the activity of the ROC domain of a
protein or dependent upon the function of the holoprotein in toto.
Whole gene KO represents a robustmethod to examine function;
however, elucidating the contribution of individual domains to
KO phenotypes is not straightforward. In the ROCO proteins,
this is complicated by the interactions between multiple enzy-
matic activities. In D. discoideum studies have been carriedout on GbpC to address this issue, investigating the contribution
of the various domains of GbpC to the chemotaxis pheno-
type (van Egmond et al., 2008). More recently, Roco4, the
D. discoideum protein most closely related to LRRK2, has
been studied as a system for modeling the impact of mutations
in LRRK2 (Gilsbach et al., 2012). Ablation of Roco4 results in
an inability to synthesize cellulose under starvation conditions,
preventing the formation of functional fruiting bodies. Finally,
the ROCO kinase QkgA has been implicated in chemotaxis
and cell proliferation although the precise mechanisms regu-
lating these links have not yet been defined (Phillips and Gomer,
2010, 2012).
Research using more complex organisms has implicated
ROCO proteins in a number of cellular phenotypes. Knockout
of LRK-1, the C. elegans LRRK ortholog, is associated with
altered polarized sorting of synaptic vesicles (Sakaguchi-Naka-
shima et al., 2007). Using a kinase dead form of LRK-1, the
authors report a kinase dependency of this phenotype; however,
the role of the ROCdomain of LRK-1 has not been directly exam-
ined. A study by Sa¨mann and coworkers examined LRK-1 in the
context of stress response and neurite outgrowth, an area of
great interest with regard to LRRK2 in human models (see
below), with their results suggesting that LRK-1 is involved in
the response to endoplasmic reticulum stress caused by expo-
sure to tunicamycin (Sa¨mann et al., 2009). Subsequent studies
have used C. elegans as a system to examine the function of
human LRRK2, a number of which have examined Parkinson’s
disease mutations located in the ROC domain (Saha et al.,
2014; Yao et al., 2013).
C. elegans also possesses a DAPK1 ortholog, with several
reports implicating this in the control of macroautophagy and
wound closure (Chuang and Chisholm, 2014; Kang and Avery,
2010). Kang and colleagues demonstrated that DAPK1 operates
downstream of the muscarinic receptors in the worm to control
the autophagic response to starvation, with knockdown or
knockout of this gene leading to reduced response (Kang
et al., 2007). An analysis of the role of DAPK1 in wound closure
in C. elegans revealed that it acts as a negative regulator of
this process, downstream of Ca+ signaling (Tong et al., 2009;
Xu and Chisholm, 2011).
Although the D. melanogaster genome does include a DAPK
ortholog (encoded by the DRAK gene), this protein does not
possess an ROC domain (Chuang and Chisholm, 2014). In
contrast, the Drosophila LRRK ortholog (dLRRK2) has been the
subject of detailed investigations, with knockout and targeted
mutation models developed. An observation directly relevant
to the biology of the ROC domain is that dLRRK KO results in
a neurodegenerative phenotype (Lee et al., 2007). However, if
just the kinase domain is removed (and the ROC domain
remains), then there is no neuronal cell death (Wang et al.,
2008). This suggests that the cellular triggers leading to cell
death following the loss of dLRRK depend upon the activity of
the ROC domain. Several studies have used Drosophila as
a model system to examine pathways linked to LRRK2
biology—for example, by identifying 4EBP1 as a putative sub-
strate (Imai et al., 2008), implicating LRRK2 in microRNA regula-
tion of translation (Gehrke et al., 2010), and suggesting that
LRRK2 is involved in membrane fusion involving the endophilin
proteins (Matta et al., 2012).Chemistry & Biology 21, July 17, 2014 ª2014 The Authors 813
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Both DAPK1 and LRRK1 KO mice have been developed. The
former have no obvious gross phenotype; however, Tu and col-
leagues used the model to examine a role for DAPK1 in NMDA
mediated brain damage following a ischemic stroke (Tu et al.,
2010). KO of LRRK1 results in osteopetrosis, although the
altered pathways leading to this are unclear (Xing et al., 2013).
KO of LRRK2 results in disruption of kidney, lung, and liver func-
tion, including the accumulation of vesicles and a-synuclein
within cells in these tissues and alterations in markers for auto-
phagy (Tong et al., 2010, 2012). Data from subsequent studies
suggest that this may be a kinase-dependent phenotype (Herzig
et al., 2011), and it is reproduced in rats lacking LRRK2 (Baptista
et al., 2013). LRRK2 KO mice have also been reported to display
increased susceptibility to an experimentally induced form of
inflammatory bowel disease, possibly due to altered nuclear
factor of activated T cells (NFAT) transcriptional regulation (Liu
et al., 2011). A number of transgenic and knockin mouse models
for LRRK2 display some neuronal phenotypes, with marked tau
pathology a characteristic of a bacterial artificial chromosome
transgenic mouse with a mutation in the ROC (the R1441G
mutation) (Li et al., 2009b).
The cellular functions of the four human ROCO proteins have
been the subject of intense scrutiny. Several reports have linked
the cellular function of LRRK1 to endosomal sorting, in particular
to trafficking of the epidermal growth factor receptor (Hanafusa
et al., 2011; Ishikawa et al., 2012). Human genetics has linked
LRRK2 to Parkinson’s disease, Crohn’s disease, multibacillary
leprosy, and cancer (Lewis andManzoni, 2012).While themolec-
ular mechanisms underpinning these associations are unclear,
there are a number of common themes that emerge. These
include inflammation, the immune system, and cell fate. How
the ROC domain contributes to these disease phenotypes is
not clear, although the location of mutations (for example, the
R1441C mutation) in the ROC domain causative for Parkinson’s
disease has focused a great deal of research on this aspect of
LRRK2 biology. At a cellular level, LRRK2 has been implicated
in a wide range of cell processes including mitochondrial
biology, synaptic vesicle cycling, macroautophagy, cytoskeletal
dynamics, and the control of translation (Cookson, 2010). A
recurring observation is an association of LRRK2 with mem-
branes, including mitochondria, autophagosomes, and synaptic
vesicles (Alegre-Abarrategui et al., 2009; Berger et al., 2010;
Biskup et al., 2006). LRRK2 has been linked to the RabGTPases,
involved in the regulation of intracellular membrane fusion events
(Beilina et al., 2014; MacLeod et al., 2013). Given the localization
of LRRK2 to membranous structures, it is possible that the ROC
domainmay fulfil a similar role to the Rabs, despite the sequence
divergence between these domains. Insights into the biological
function of the LRRK2 ROC domain are provided by experiments
studying PD mutations in the ROC and kinase domain. Several
of these investigations report a divergence between the
impact of mutations in the ROC and the kinase domains. These
data—for example, the differential impact of the R1441C and
G2019S on translational phenotypes linked to LRRK2 (Gehrke
et al., 2010)—suggest that the cellular function of the ROC
domain may be distinct from that of the kinase domain.
DAPK1 has been implicated in cell death pathways—in partic-
ular, type II autophagic cell death (Bialik and Kimchi, 2006; Deiss814 Chemistry & Biology 21, July 17, 2014 ª2014 The Authorset al., 1995). Several themes emerge from studies of DAPK1,
including macroautophagy and the regulation of membrane
vesicle biology (Inbal et al., 2002). Both autophagy and wound
healing, identified as being linked to DAPK1 in C. elegans,
have been linked to the function of the mammalian gene (Bialik
and Kimchi, 2010; Kuo et al., 2006). Although the biochemistry
of the ROC domain of DAPK1 has been investigated, the impact
of this domain on pathways downstream of this protein has not
and is likely to be a highly fruitful line of enquiry in the future.
The cellular function of MASL1 is the least understood of the
human ROCO proteins. MASL1 was originally identified as a
gene amplified in malignant fibrous histiocytomas, implicating
it in the control of cell fate and division (Sakabe et al., 1999).
The cellular studies that have been carried out since then
support this implication, suggesting a role for MASL1 in the
regulation of the ERK pathway to influence erythroid differentia-
tion of CD34 (+) cells (Kumkhaek et al., 2013) and in necrotic cell
death (Dihanich et al., 2014).
ROC Domains as Pharmacological Targets
Given the important role played in human disease by proteins
containing ROC domains, it is perhaps unsurprising that ROC
domains are considered as potential therapeutic targets. At
present, the prevailing strategy to target LRRK2 and DAPK1 in
a disease context is tomodulate kinase activity. Kinase inhibitors
have been developed for both LRRK2 and DAPK1 (Deng et al.,
2011; Okamoto et al., 2009), with a large number of small
molecule inhibitors reported for LRRK2 (Choi et al., 2012; Reith
et al., 2012; Zhang et al., 2012). In contrast, there is a single pub-
lished report of targeting ROC biology, investigating both LRRK2
and DAPK1 (Klein et al., 2009). Klein and coworkers expressed
the ROC domain of LRRK2 as a transgene alongside full-length
LRRK2 and observed an inhibition of LRRK2 activity. This
echoes an earlier report targeting the Dictyostelium protein
Pats1 (Abysalh et al., 2003). In this study, expression of the
Pats1 ROC domain was able to exert a dominant negative effect
on downstream cytokinetic pathways, suggesting that the inter-
ruption of complex formation acts to inhibit function. These data
have a number of implications for ROC domain biology; howev-
er, the transgenic approaches required to translate these
findings into a viable in vivo therapeutic strategy are not yet
amenable for application in a clinical setting.
As our understanding of the function of the ROC domain
increases, so do opportunities to target its biology and patholog-
ical consequences (Figure 4). In particular, there is the potential
to benefit from previous attempts to target the activity of
GTPases. Two case studies are instructive: that of Ras in human
cancer and that of G protein a subunits in G protein coupled
receptor-signaling pathways.
Following the identification of the Ras genes (H-Ras, K-Ras,
and N-Ras), and the close association between point mutations
in these genes and human cancer, substantial efforts have been
made to correct their oncogenic activity (Karnoub andWeinberg,
2008). As it became clear that the biochemical fault linking these
proteins to tumor formation was a reduction in GTPase activity,
altering the downstream effects of this become a priority target
for the cancer research field. Although a great deal is now known
about the structural basis for GTP hydrolysis by Ras proteins,
efforts to target this pathway have focused on the downstream
Figure 4. Strategies to Target ROC Domain Activity
Image of C. tepidum ROCO protein derived from Protein Data Bank reference
3PDU (Gotthardt et al., 2008).
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proteins and these effectors, altering the binding of proteins
directly regulating GTP hydrolysis or guanine exchange factors,
or by manipulating the processing and cellular location of Ras
proteins. This strategy derives from the intrinsic difficulties of
altering the rate of GTP hydrolysis in a specific manner and the
lack of potential small molecule binding pockets on Ras to facil-
itate allosteric regulation (Downward, 2003). Recent successes
include using small molecules to modulate the interaction
between K-Ras and Son of Sevenless (SOS), a GEF (Maurer
et al., 2012), directly inhibiting the interactions between H-Ras
and Raf with small molecules derived from an in silico screen
(Shima et al., 2013) and disrupting the interaction between
K-Ras and PDEd, a prenyl binding protein that acts to govern
the cellular localization of K-Ras (Zimmermann et al., 2013).
Most recently, Ostrem and coworkers have demonstrated that
pharmacological targeting of K-Ras via an allosteric approach
is tractable, and they were able to demonstrate mutation-spe-
cific inhibition—a finding of obvious relevance to LRRK2 (Ostrem
et al., 2013). While it is important not to underestimate the scale
of the challenge, these advances provide hope for targeting ROC
domain biology.
Heterotrimeric G proteins are involved in the control of a range
of cellular functions, and similar to Ras the pathways within
which they function have been implicated in oncogenesis. Efforts
to target G protein a subunits, the subunit of the heterotrimeric G
protein complex responsible for the binding and hydrolysis of
GTP, have resulted in the derivation of a number of compounds
that modulate the release and exchange of guanosine nucleo-
tides. Examples include suramin (Butler et al., 1988) and imida-
zopyrazines (Ayoub et al., 2009), molecules that are thought to
inhibit nucleotide exchange (Smrcka, 2013). YM-254890 oper-
ates via a similar mechanism and has been cocrystalized with
Gaq (Nishimura et al., 2010). This provides a molecular insight
into the mechanism of action, suggesting that YM-254890
restricts the freedom of movement for the subunit and inhibits
the release of GDP from the active site.
What is revealing about the experience of targeting G proteins
and Ras is that advances have been achieved not by directly
targeting the active site of these proteins but by acting onprotein-protein interactions or regulatory mechanisms. For the
ROCO proteins, this is hindered by the lack of validated interact-
ing proteins that modulate guanosine nucleotide hydrolysis or
exchange. Candidate GAPs and/or GEFs have been identified
for LRRK2; however, the spatial details of these relationships
remain obscure (Biosa et al., 2013; Haebig et al., 2010). Further-
more, due to the low affinity of ROCO proteins for guanine
nucleotides (in the mM range), it is still controversial whether
ROCO require GEFs for nucleotide exchange. Therefore, robust
validation of authentic in vivo GEFs and/or GAPs for ROCO pro-
teins is needed before considering them as potential targets.
More optimistically, the multidomain proteins containing ROC
domains benefit from having a number of putative protein-pro-
tein interaction candidates within the same open reading frame.
Indeed, what structural data exist for proteins containing ROC
domains suggest that these interactions are critical for function.
It is also notable that the sequence divergence between ROC
domains and the small GTPases suggests that it may be possible
to design molecules that will interact specifically with ROCO
proteins. On a cautionary note, there are still major gaps in our
understanding of the consequences of inhibiting or potentiating
signaling pathways regulated by ROC domain GTP and GDP
binding. Even for those proteins studied most intensely,
DAPK1 and LRRK2, we do not have a validated model for the in-
teractions between the enzymatic activities of these proteins.
Given the important boost to research provided by the availabil-
ity of specific kinase inhibitor tools for these proteins, it is likely
that the development of tool compounds specifically targeting
ROC domain function will prove invaluable for delineating regu-
latory mechanisms centered on this domain.
Conclusions
From a standing start in 2002, our understanding of ROC domain
structure and function has advanced at a startling rate, primarily
driven by the realization of the role that ROC-domain-containing
proteins play in human disease. It is likely that the coming years
will provide even greater insights into the function of this domain,
in particular with higher resolution structural data in the context
of multidomain fragments of ROCO proteins. The urgent require-
ment for novel therapies to treat the disorders linked to proteins
containing ROC domains highlights the need to examine the
feasibility of targeting ROC biology, despite the huge challenge
that this represents, and this is sure to be a major focus of
research into the proteins in the future.
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